Jubilant’s therapeutically aligned clinical development capabilities provide collaborators a seamless transition from preclinical through translational and early stage development. This is further augmented by Jubilant’s ability to provide global access to late stage development (Phase II-IV) across Europe, USA and India.

Clinsys Research, the clinical research groups within DDDS, provides pharmaceutical, biotechnology and medical device companies with a broad range of clinical research services in support of Phase I-IV drug and device development, including project management, clinical monitoring, scientific and medical support, investigator and patient recruitment, site management, biostatistics, data management, EDC, drug safety, quality assurance, regulatory affairs, strategic sourcing and medical writing.

Highly efficient globally leveraged project management teams are supported by therapeutic experts in areas of dermatology, central nervous system, oncology, respiratory and cardiovascular providing collaborators with strategic and operational support from study design through regulatory approvals.

The Clinical Research group seamlessly integrates with customers or Jubilant’s discovery and pre-clinical infrastructure to provide high quality and highly efficient translational and clinical development solutions to include:

• Scientific foundation
  • Therapeutic Program Strategists (Clinsys TPS^TM)
  • Phase I unit (BA/BE, PK, generics and pre-formulation
  • Trial design
  • Scientific advisory board per each therapeutic area
• Sites/ Patients access
  • Global investigator network
  • Global feasibility
  • Expedited patient enrollment
  • Site training and validation
• Technology
  • Clinsys Trialstat CA, the first software as a service (SaaS)- based electronic data capture (EDC) system in the industry.
  • Strategic alliances with vendors across multiple platforms and systems.
• Precision, execution and accountability
  • Clinsys Global Project Solution (Clinsys GPS) Executive steering committee assigned to each project.
  • Shared metrics/ transparent processes